Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

被引：2
|
作者：
Weng, Guangyang [1 ,2 ]
Zhang, Yu [1 ]
Yu, Guopan [1 ]
Xu, Na [1 ]
Sun, Zhiqiang [3 ]
Lin, Dongjun [4 ]
Liang, Xinquan [5 ]
Deng, Lan [6 ]
Xiao, Jie [7 ]
Zhang, Hongyu [8 ]
Guo, Ziwen [9 ]
Jin, Hua [1 ]
Du, Xin [10 ]
Liu, Qifa [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Shenzhen Univ, Peoples Hosp Shenzhen 2, Affiliated Hosp 1, Dept Hematol, Shenzhen, Peoples R China
[3] Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Hematol, Shenzhen, Peoples R China
[5] First Peoples Hosp Chenzhou, Dept Hematol, Chenzhou, Peoples R China
[6] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Hematol, Shanghai, Peoples R China
[7] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hematol, Guangzhou, Peoples R China
[8] Peking Univ, Dept Hematol, Shenzhen Hosp, Shenzhen, Peoples R China
[9] Zhongshan City Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China
[10] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Dept Hematol, Shenzhen, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158762
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2025 / 2026
页数：2
相关论文
共 50 条
  • [41] Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
    de Camargo Magalhaes, Eduardo Sabino
    Hubner, Stefan Edward
    Brown, Brandon Douglas
    Qiu, Yihua
    Kornblau, Steven Mitchell
    LEUKEMIA, 2024, 38 (05) : 1046 - 1056
  • [42] Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
    Eduardo Sabino de Camargo Magalhães
    Stefan Edward Hubner
    Brandon Douglas Brown
    Yihua Qiu
    Steven Mitchell Kornblau
    Leukemia, 2024, 38 : 1046 - 1056
  • [43] Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases
    Wang, Na
    He, Jing
    Liu, Fang
    CHEMOTHERAPY, 2022, 67 (03) : 178 - 182
  • [44] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
    Daver, Naval
    Perl, Alexander E.
    Maly, Joseph
    Levis, Mark
    Ritchie, Ellen
    Litzow, Mark
    McCloskey, James
    Smith, Catherine C.
    Schiller, Gary
    Bradley, Terrence
    Tiu, Ramon, V
    Naqvi, Kiran
    Dail, Monique
    Brackman, Deanna
    Siddani, Satya
    Wang, Jing
    Chyla, Brenda
    Lee, Paul
    Altman, Jessica K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +
  • [45] Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Mannelli, Francesco
    Ciolli, Gaia
    Pasquini, Andrea
    Fasano, Laura
    Quinti, Elisa
    Guglielmelli, Paola
    Mannarelli, Carmela
    Pancani, Fabiana
    Zizza, Michela
    Signori, Leonardo
    Vannucchi, Alessandro M.
    Gianfaldoni, Giacomo
    BLOOD, 2022, 140 : 9008 - 9009
  • [46] Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes
    Ghorab, Ahmad
    Litzow, Mark
    Gangat, Naseema
    Al-Kali, Aref
    Shah, Mithun
    Murthy, Hemant
    Alkhateeb, Hasan
    Begna, Kebede
    Patnaik, Mrinal
    Foran, James
    Badar, Talha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S306 - S306
  • [47] VENETOCLAX PLUS HYPOMETHYLATING AGENTS (HMAS) FOR RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) IS AN EFFECTIVE AND MANAGEABLE REGIMEN IN THE OUTPATIENT SETTING: A REAL-LIFE EXPERIENCE
    Nanni, J.
    Papayannidis, C.
    Cristiano, G.
    Marconi, G.
    Sartor, C.
    Parisi, S.
    Ottaviani, E.
    Bandini, L.
    Testoni, N.
    Baldazzi, C.
    Ricci, P.
    Bezzi, C. Di Giovanni
    Abd-Alatif, R.
    Paolini, S.
    Cavo, M.
    Curti, A.
    HAEMATOLOGICA, 2020, 105 : S94 - S94
  • [48] Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia
    Kennedy, Vanessa E.
    Hui, Gavin
    Gaut, Daria
    Mittal, Varun
    Oliai, Caspian
    Muffly, Lori S.
    Logan, Aaron C.
    Mannis, Gabriel N.
    BLOOD, 2020, 136
  • [49] Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia
    Kennedy, Vanessa E.
    Hui, Gavin
    Azenkot, Tali
    Gaut, Daria
    Wieduwilt, Matthew J.
    Oliai, Caspian
    Jonas, Brian A.
    Mittal, Varun
    Logan, Aaron C.
    Muffly, Lori S.
    Mannis, Gabriel N.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : E191 - E194
  • [50] Venetoclax and hypomethylating agents inFLT3-mutated acute myeloid leukemia
    Aldoss, Ibrahim
    Zhang, Jianying
    Mei, Matthew
    Al Malki, Monzr M.
    Arslan, Shukaib
    Ngo, Dat
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Salhotra, Amandeep
    Koller, Paul
    Khaled, Samer
    Artz, Andrew
    Snyder, David
    Nakamura, Ryotaro
    Forman, Stephen J.
    Stein, Anthony S.
    Marcucci, Guido
    Pullarkat, Vinod
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (10) : 1193 - 1199
12345